According to FutureWise analysis, the market for Acute Myeloid Leukaemia is expected to reach US$ 3.63 billion by 2031 at a CAGR of 10.37% over the forecast period of 2023-2031.
The complex hematologic malignancy known as acute myeloid leukaemia (AML) is characterised by the clonal expansion of myeloid blasts in the bone marrow, and/or other organs. This type of acute leukaemia, which is more common in adults, is responsible for the majority of leukemia-related deaths in the United States each year. Large chromosomal translocations and mutations in the genes involved in hematopoietic proliferation are the causes of the rise in poorly formed myeloid cells. AML is a very heterogeneous disease; although cases can be divided into groups with favorable, intermediate, and unfavorable risks based on their cytogenetic profiles, prognosis within these groups varies greatly.
The typical age of diagnosis is 67 years, with 54% of patients receiving their diagnosis at 65 or older (and around a third of those receiving their diagnosis at or below 75 years old). As a result, the incidence of AML appears to be increasing as the population ages. Prolonged exposure to petrochemicals, solvents like benzene, insecticides, and ionizing radiation are environmental factors that have long been known to raise the risk of AML. Individual prognosis and management have been improved due to the discovery of recurrent genetic variants such as FLT3-ITD, NMP1, and CEBPA.
FutureWise Market Research has published a report that provides an insightful analysis of Acute Myeloid Leukemia Market trends affecting overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=177%20&type=requestsample
Acute Myeloid Leukemia Market Segmentation:
By Drug Class
• Tyrosine Kinase Inhibitors
• Hedgehog Pathway Inhibitors
• Topoisomerase 2 Inhibitors
• Others

By End User
• Hospital
• Clinic
• Others

By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Competitive Landscape in Acute Myeloid Leukemia Market:

• Johnson & Johnson Private Limited
• Pfizer Inc.
• Abbott
• AstraZeneca
• Bayer
• Celgene Corporation
• Ambit Biosciences Corporation
• Cyclacel Pharmaceuticals Inc.
• Novartis AG and Sanofi.

Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=177&license=multi
**Objectives of this Study: **
1. To provide a comprehensive analysis of the Acute Myeloid Leukemia Market By Drug Class, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Related market:
Some of the other related markets that you might be interested in are listed as below:

Chronic Lymphocytic Leukemia Therapeutics Market
Chronic Myeloid Leukemia Treatment Market
Chronic Lymphocytic Leukemia Market
Leukemia Therapeutics Market

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com